Journey Medical Corporation Reports Strong Q4 2025 Earnings with Emrosi Launch Success
- Emrosi Sales Surge: Journey Medical's oral rosacea treatment, Emrosi, launched in 2025, achieved $14.7 million in net sales since its release, indicating strong market demand and effective promotional strategies, which are expected to further drive revenue growth.
- Improved Financial Performance: The company reported total revenues of $61.9 million for 2025, reflecting a 10% increase, with gross margin rising to 66.2%, demonstrating solid profitability and growth potential despite competitive pressures on legacy products.
- Prescription Volume Increase: Emrosi's prescription volume surged nearly 50% sequentially in Q4 2025, with over 3,500 unique dermatology prescribers writing at least one script, indicating significant market acceptance and trust among physicians.
- Optimistic Future Outlook: Management expects to maintain positive adjusted EBITDA in 2026 and plans to launch one or two incremental dermatology products, showcasing a proactive strategic approach to expanding product lines and market share.
Trade with 70% Backtested Accuracy
Analyst Views on DERM
About DERM
About the author
Journey Medical Reports FY 2025 Financial Results with Mixed Performance
- Revenue Growth: Journey Medical reported FY 2025 revenue of $61.6 million, reflecting a 9.7% year-over-year increase, although it missed analyst expectations by $3.05 million, indicating volatility in market demand.
- Gross Margin Improvement: The gross margin for FY 2025 improved to 66.2% from 62.8% in FY 2024, driven by increased sales of higher-margin products like Emrosi™ and Qbrexza®, showcasing the company's success in optimizing its product mix.
- Increase in SG&A Expenses: Selling, general, and administrative expenses rose to $44.4 million in FY 2025, a 10% increase from $40.2 million in FY 2024, primarily due to incremental operational activities related to the launch and commercialization of Emrosi™, which may impact future profitability.
- Reduction in Net Loss: The net loss for FY 2025 was $11.4 million, or $0.47 per share, an improvement from a net loss of $14.7 million, or $0.72 per share in FY 2024, indicating the company's efforts in cost control and efficiency enhancement.
Journey Medical Corporation Reports Strong Q4 2025 Earnings with Emrosi Launch Success
- Emrosi Sales Surge: Journey Medical's oral rosacea treatment, Emrosi, launched in 2025, achieved $14.7 million in net sales since its release, indicating strong market demand and effective promotional strategies, which are expected to further drive revenue growth.
- Improved Financial Performance: The company reported total revenues of $61.9 million for 2025, reflecting a 10% increase, with gross margin rising to 66.2%, demonstrating solid profitability and growth potential despite competitive pressures on legacy products.
- Prescription Volume Increase: Emrosi's prescription volume surged nearly 50% sequentially in Q4 2025, with over 3,500 unique dermatology prescribers writing at least one script, indicating significant market acceptance and trust among physicians.
- Optimistic Future Outlook: Management expects to maintain positive adjusted EBITDA in 2026 and plans to launch one or two incremental dermatology products, showcasing a proactive strategic approach to expanding product lines and market share.
Journey Medical (DERM) Q3 Earnings: Analyzing Key Metrics Against Estimates
Journey Medical Corporation Financial Performance: For Q3 2025, Journey Medical Corporation reported a revenue of $17.63 million, a 20.5% increase year-over-year, but fell short of the Zacks Consensus Estimate by 0.39%. The EPS was -$0.09, slightly better than the previous year's -$0.12 but below the consensus estimate of -$0.08.
Investor Insights: Investors are closely monitoring revenue and earnings changes to gauge the company's financial health, with key metrics providing a clearer picture of performance compared to year-ago numbers and analyst estimates.
Technological Advancements in Investment: The article highlights the transformative impact of artificial intelligence and its potential convergence with quantum computing, suggesting significant wealth-building opportunities for investors.
Investment Recommendations: A special report titled "Beyond AI: The Quantum Leap in Computing Power" is mentioned, offering insights into stocks poised to benefit from advancements in quantum computing, along with a free report on the "7 Best Stocks for the Next 30 Days."
Journey Medical Corporation Presents Efficacy Data Analysis from Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial at the 2025 Fall Clinical Dermatology Conference
FDA Approval and Efficacy: Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) is FDA-approved for treating inflammatory lesions of rosacea in adults, showing superior efficacy in clinical trials compared to both placebo and doxycycline.
Clinical Trial Results: In a pooled analysis of two Phase 3 trials, 62.7% of subjects treated with DFD-29 achieved treatment success, significantly outperforming the 39.0% success rate of Oracea and 28.2% for placebo, with notable reductions in inflammatory lesions.
Safety Profile: DFD-29 was well tolerated in trials, with no major safety issues reported, and the incidence of treatment-emergent adverse events was comparable across all treatment groups.
Market Position and Commitment: Journey Medical Corporation aims to expand Emrosi's market presence, emphasizing its potential as a standard treatment for rosacea and its commitment to improving patient outcomes in dermatology.
Journey Medical Releases Combined Phase 3 Data for Emrosi in Treating Rosacea
Clinical Data Presentation: Journey Medical Corporation presented pooled Phase 3 data for DFD-29 (Emrosi) at the 2025 Fall Clinical Dermatology Conference, focusing on its efficacy in treating inflammatory lesions of rosacea in adults.
Efficacy Results: The analysis showed that 62.7% of patients treated with DFD-29 achieved treatment success, significantly outperforming the Oracea group (39.0%) and the placebo group (28.2%).
HC Wainwright & Co. Begins Coverage of Journey Medical with a Buy Rating and Sets Price Target at $13
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
Journey Medical Reports FY 2025 Financial Results with Mixed Performance
- Revenue Growth: Journey Medical reported FY 2025 revenue of $61.6 million, reflecting a 9.7% year-over-year increase, although it missed analyst expectations by $3.05 million, indicating volatility in market demand.
- Gross Margin Improvement: The gross margin for FY 2025 improved to 66.2% from 62.8% in FY 2024, driven by increased sales of higher-margin products like Emrosi™ and Qbrexza®, showcasing the company's success in optimizing its product mix.
- Increase in SG&A Expenses: Selling, general, and administrative expenses rose to $44.4 million in FY 2025, a 10% increase from $40.2 million in FY 2024, primarily due to incremental operational activities related to the launch and commercialization of Emrosi™, which may impact future profitability.
- Reduction in Net Loss: The net loss for FY 2025 was $11.4 million, or $0.47 per share, an improvement from a net loss of $14.7 million, or $0.72 per share in FY 2024, indicating the company's efforts in cost control and efficiency enhancement.
Journey Medical Corporation Reports Strong Q4 2025 Earnings with Emrosi Launch Success
- Emrosi Sales Surge: Journey Medical's oral rosacea treatment, Emrosi, launched in 2025, achieved $14.7 million in net sales since its release, indicating strong market demand and effective promotional strategies, which are expected to further drive revenue growth.
- Improved Financial Performance: The company reported total revenues of $61.9 million for 2025, reflecting a 10% increase, with gross margin rising to 66.2%, demonstrating solid profitability and growth potential despite competitive pressures on legacy products.
- Prescription Volume Increase: Emrosi's prescription volume surged nearly 50% sequentially in Q4 2025, with over 3,500 unique dermatology prescribers writing at least one script, indicating significant market acceptance and trust among physicians.
- Optimistic Future Outlook: Management expects to maintain positive adjusted EBITDA in 2026 and plans to launch one or two incremental dermatology products, showcasing a proactive strategic approach to expanding product lines and market share.
Journey Medical (DERM) Q3 Earnings: Analyzing Key Metrics Against Estimates
Journey Medical Corporation Financial Performance: For Q3 2025, Journey Medical Corporation reported a revenue of $17.63 million, a 20.5% increase year-over-year, but fell short of the Zacks Consensus Estimate by 0.39%. The EPS was -$0.09, slightly better than the previous year's -$0.12 but below the consensus estimate of -$0.08.
Investor Insights: Investors are closely monitoring revenue and earnings changes to gauge the company's financial health, with key metrics providing a clearer picture of performance compared to year-ago numbers and analyst estimates.
Technological Advancements in Investment: The article highlights the transformative impact of artificial intelligence and its potential convergence with quantum computing, suggesting significant wealth-building opportunities for investors.
Investment Recommendations: A special report titled "Beyond AI: The Quantum Leap in Computing Power" is mentioned, offering insights into stocks poised to benefit from advancements in quantum computing, along with a free report on the "7 Best Stocks for the Next 30 Days."
Journey Medical Corporation Presents Efficacy Data Analysis from Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial at the 2025 Fall Clinical Dermatology Conference
FDA Approval and Efficacy: Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) is FDA-approved for treating inflammatory lesions of rosacea in adults, showing superior efficacy in clinical trials compared to both placebo and doxycycline.
Clinical Trial Results: In a pooled analysis of two Phase 3 trials, 62.7% of subjects treated with DFD-29 achieved treatment success, significantly outperforming the 39.0% success rate of Oracea and 28.2% for placebo, with notable reductions in inflammatory lesions.
Safety Profile: DFD-29 was well tolerated in trials, with no major safety issues reported, and the incidence of treatment-emergent adverse events was comparable across all treatment groups.
Market Position and Commitment: Journey Medical Corporation aims to expand Emrosi's market presence, emphasizing its potential as a standard treatment for rosacea and its commitment to improving patient outcomes in dermatology.
Journey Medical Releases Combined Phase 3 Data for Emrosi in Treating Rosacea
Clinical Data Presentation: Journey Medical Corporation presented pooled Phase 3 data for DFD-29 (Emrosi) at the 2025 Fall Clinical Dermatology Conference, focusing on its efficacy in treating inflammatory lesions of rosacea in adults.
Efficacy Results: The analysis showed that 62.7% of patients treated with DFD-29 achieved treatment success, significantly outperforming the Oracea group (39.0%) and the placebo group (28.2%).
HC Wainwright & Co. Begins Coverage of Journey Medical with a Buy Rating and Sets Price Target at $13
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
